Background-Protein kinase C (PKC) is involved in vascular smooth muscle cell (VSMC) activation, but little is known about its function in vascular pathology. We aimed at assessing the role of PKC in the development of restenosis. Methods and Results-Rat models of aortic balloon injury with or without subsequent stenting were used. Rats were treated with the selective PKC activator receptor for activated protein kinase C (RACK), the selective PKC inhibitor V1-2, or saline. Both down-stream cascades of the platelet-derived growth factor receptor via extracellular signal-regulated kinase and Akt, respectively, were evaluated in vivo and in VSMC cultures. Intimal hyperplasia with luminal obliteration developed in saline-treated balloon-injured rat aortas (20.3Ϯ8.0%), and RACK significantly promoted neointima development (32.4Ϯ4.9%, Pϭ0.033), whereas V1-2 significantly inhibited luminal narrowing (9.2Ϯ4.3%, Pϭ0.039). PKC inhibition led to significantly reduced VSMC extracellular signal-regulated kinase phosphorylation in vivo, whereas Akt phosphorylation was not markedly affected. Neointimal proliferation in vivo and platelet-derived growth factor-induced VSMC proliferation/migration in vitro were significantly inhibited by V1-2.
protein kinase C (PKC) family. 1 Recent developments of isozyme-specific activators and inhibitors provided us with tools to differentially study isozyme-specific functions. It appears that ␣PKC and PKC, together with the atypical PKCs, mediate cell proliferation and survival, whereas ␦PKC and PKC are important regulator of apoptosis. 2 PKC has been shown to play a role in promoting early medial infiltration in a carotid artery balloon injury model, thus aiding in controlling neointimal inflammation and growth. 3 The ␦PKC and PKC isozymes have been shown to play opposing roles in cardiac ischemia and reperfusion, with PKC mediating cardioprotection against ischemic injury and ␦PKC mediating reperfusion-induced cell damage. 2, 4 Selective sustained PKC inhibition has been shown to suppress chronic inflammation and the development of perivascular fibrosis in a murine cardiac transplantation model. 5 In hypertensive rats, PKC inhibition prolonged survival, reduced cardiac hypertrophy, excessive fibrosis, vascular remodeling, inflammation, and corrected cardiac dysfunction. 6 However, the selective PKC activator receptor for activated protein kinase C (RACK) conferred cardioprotection from ischemiareperfusion injury under cell culture conditions and in animal models of acute myocardial infarction, when delivered acutely before the ischemic event. 4, 7, 8 PKC activation may appear as a "double-edged sword", acutely increasing mito-chondrial function and preventing cell death, but chronically increasing inflammatory responses. The complex involvement of PKC isozymes in cardiovascular physiology needs further research before targets for therapeutic interventions can be identified. Especially the role of PKC on vascular remodeling is not known. In this study, we sought to investigate the role of PKC on the development of intimal hyperplasia after mechanical injury.
Methods

Rat Restenosis Models
Male Sprague-Dawley rats weighing 550 to 600 g were purchased from Harlan. All rats were housed under conventional conditions in the animal care facilities. All animals received humane care in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals. Aortic endothelial denudation and stent placement (Yukon Plus, 2.5ϫ12 mm; Translumina) was performed as previously reported 9 and described in the supplemental data, available online at http://circ.ahajournals.org.
Animals were treated with the selective PKC activator, RACK, 7 the selective PKC inhibitor, V1-2, 10 the cellpenetrating TAT carrier peptide (TAT 47-57 ), or saline. Both PKC modifying peptides were conjugated to TAT 47-57 , which greatly enhances cell permeation of these intracellularly acting peptides in vivo and in vitro. The selectivity of the peptides to PKC was previously reported in many independent studies in vitro 7,10 and in vivo. 11 All drugs were administered in a sustained fashion via implanted osmotic pumps (Alzet), which were replaced every second week. Peptides were each delivered at 3 mg/kg per day. Denuded aortas were harvested after 4 weeks and stented aortas after 6 weeks.
Histology
Cross-sections of denuded aortas were stained with Elastica van Giesson and Masson-Goldner trichrome (Merck). Cell proliferation was detected by PCNA staining (Dako) after antigen retrieval (Dako) using the AP development system (Zytomed). Paraffin sections were stained for ␣-actin (red; Sigma), 4Ј,6-diamidino-2-phenylindole (DAPI) (blue; Invitrogen), and elastin (green; Abcam). Quantification of neointimal fibrosis and cell density was performed as outlined in supplemental data. Reendothelialization was determined by RECA-1 immunofluorescence stainings (Serotec). Aortas housing stents were processed as previously reported, 9 sectioned at 5-m thickness, and stained with hematoxylin and eosin. For details, please see supplemental data.
Optical Coherence Tomography (OCT) Imaging
OCT images were obtained with the M2 OCT imaging system (LightLab Imaging). Motorized pullback was performed at a rate of 1.0 mm per second as described in the supplemental data. Neointimal cross-sectional areas were measured, and luminal obliteration was calculated.
Western Blot Analysis
Rat aortic tissue was homogenized in homogenization buffer (50 mmol/L Tris⅐HCl, pH 7.5/150 mmol/L NaCl/1% SDS/protease inhibitor cocktail [Sigma-Aldrich]). After removal of tissue debris by centrifugation, 20 or 50 g of proteins were separated on an 8 or 10% SDS-PAGE and were transferred to immobilon-P transfer membrane (Millipore). Antibodies against plateletderived growth factor (PDGF) receptor-␤, phosphorylated Akt (S453) and extracellular signal-regulated kinase (ERK), and ␤-actin (Santa Cruz Biotechnology, Inc; Cell Signaling Technology) were used for immunoblotting followed by HRP-conjugated antimouse, rabbit or goat IgG antibodies (GE Healthcare; Santa Cruz Biotechnology, Inc). All samples were loaded equally for each gel based on protein concentration.
In Vitro VSMC and Endothelial Cell (EC) Culture Assays
Proliferation assays with mitogen-stimulated rat aortic VSMC (PDGF 25 ng/mL) and EC (VEGF 10 ng/mL) were performed in the presence of TAT 47-57 only (control), RACK, or V1-2 (1 mol/L each). To assess VSMC migration, a standard scratch was made across a VSMC culture slide, and the number of cells that migrated into this "wound" within 4 days was counted. The TUNEL assay (Invitrogen) was used to detect apoptotic cells. For details, please see supplemental data.
In Vitro PKC Translocation Assay and Western Blot Analysis
Levels of active PKC in VSMC were determined by cell fractionation and Western blot analysis. Cells were pretreated with V1-2 or TAT 47-57 and stimulated with 25 ng/mL PDGF as outlined in supplemental data. Cells were homogenized, spun, and supernatants were collected. All samples were separated by 10% SDS-PAGE, and the proteins were transferred to immobilon-P transfer membranes for immunoblotting. Akt, ERK, phosphorylated Akt, and ERK levels were measured as described above.
Statistical Analysis
Data are presented as meanϮSD. Comparisons were done by ANOVA between groups with Bonferroni post hoc tests (SPSS). PϽ0.05 was considered significant.
Results
Rat Restenosis Models
All denudation and stenting procedures were tolerated well by the animals and no stent-related complications occurred. All animals survived the study period, and all stents were suitable for OCT imaging and histological evaluation.
Intimal Hyperplasia in Balloon-Injured Aortas
Intimal hyperplasia developed in denuded rat aortas as determined 4 weeks after aortic balloon injury ( Figure 1A ). Histology revealed a high density of spindle-shaped cells and only very few mononuclear inflammation cells. Trichrome staining showed a cell-rich neointima containing fibrotic connective tissue ( Figure 1B ). Cell proliferation, detected by PCNA staining, was observed in 19Ϯ6, 25Ϯ4, and 20Ϯ4% of neointimal cells in the saline, RACK, and TAT 47-57 groups, respectively, and was significantly reduced by V1-2 (9Ϯ3%, Pϭ0.003 versus saline) ( Figure 1C ). Planimetric measurements showed that luminal obliteration in salinetreated animals was approximately 20% and was not affected by the carrier peptide TAT 47-57 . Interestingly, sustained treatment with the PKC activator, RACK, significantly promoted neointima development, whereas sustained PKC inhibition with V1-2 significantly inhibited luminal narrowing ( Figure 1D ). Accordingly, the maximal plaque thickness in the RACK group was significantly greater than with V1-2 ( Figure 1E ). Although the total neointimal areas differed among groups, the fractional areas of neointimal fibrosis (35Ϯ5, 36Ϯ5, 36Ϯ6, and 33Ϯ5%; Pϭ0.704) and the VSMC densities (24Ϯ5, 28Ϯ10, 23Ϯ5, and 22Ϯ5 VSMCs per 100 m 2 of neointimal crosssectional area; Pϭ0.643) ( Figure 1F ) were similar for saline, RACK, TAT 47 to 57 , and V1-2, respectively. We found virtually complete reendothelialization 4 weeks after denuda- 
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Circulation September 14, 2010 tion in all slides without differences related to the treatment with PKC modulators ( Figure 1G ).
In Vivo VSMC PDGF Pathway Activation
Both down-stream cascades of the PDGF pathway controlling VSMC cell cycle ( Figure 2A ) were explored. The levels of PDGF receptor expression were not affected by PKC modulation ( Figure 2B ). V1-2 administration led to a significantly reduced ERK phosphorylation, suggesting an involvement of PKC in ERK activation ( Figure 2C ). Neither RACK nor V1-2 markedly affected Akt phosphorylation ( Figure 2D ).
In Vitro VSMC and EC Culture Assays
We set out to determine whether PKC plays a direct role in VSMC and EC proliferation and VSMC migration. First, PDGF-induced PKC activation was determined. PKC translocation (or movement from the cell soluble to the cell particulate fraction) is an established method to assess PKC activation. 12 We found that PDGF stimulation significantly activated PKC ( Figure 3A ) and that this activation was blocked by pretreatment of the cells with V1-2. We further show that VSMC proliferation induced by PDGF treatment was moderately stimulated by RACK and significantly inhibited by V1-2 treatment ( Figure 3B ). We also performed the assay with 100 ng/mL of PDGF stimulation and observed similar magnitudes of growth enhancement and significant inhibition by treatment with V1-2 (data not shown). VSMC migration was assessed in culture slide scratch assays ( Figure 3C ) and revealed that VSMC migration was similarly influenced by PKC modulation. We found significant stimulation of VSMC migration by RACK in vitro and significant inhibition by V1-2 ( Figure 3D ). Cell proliferation of VEGF-stimulated EC in vitro is quantified in Figure 3E and depicted in Figure 3F . EC proliferation was significantly stimulated by RACK and significantly inhibited with V1-2. A possible implication of PKC modulators on VSMC apoptosis was further investigated using the TUNEL assay ( Figure 3G ). There was mild reduction of apoptosis by RACK, but we found significantly increased numbers of apoptotic VSMCs with V1-2 treatment ( Figure 3H ).
Effect of V1-2 Treatment on Down-Stream Signaling of PDGF
To investigate the molecular mechanism of VSMC growth inhibition by V1-2 treatment, we next determined ERK and Akt activation, which are postulated to play a role in VSMC proliferation. 13 As demonstrated by Western blot analysis, 5 minutes of PDGF stimulation significantly increased the levels of phosphorylated ERK and Akt, but V1-2 treatment did not have a significant effect at this time point ( Figure 4A ). However, after 6 hours of V1-2 treatment, there was a significant decrease in phosphorylated ERK levels in cells treated with or without PDGF as compared with cells treated with control peptide ( Figure 4B ). Similar effects of V1-2 on 
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Akt and phosphorylated Akt were also found. Although there was no effect of V1-2 treatment after 5 minutes with PDGF, there was a significant decrease in the levels of phosphorylation ratio of Akt after 6 hours. Because PDGF signaling is long lasting in injured vessels, such changes may be physiologically relevant. Together, our data suggest that PKC inhibition of PDGF-induced VSMC proliferation is likely mediated, at least in part, through inhibition of ERK and Akt activation. Figure 5A shows histological cross-sections of the stented aortas. The stent struts were eliminated during the processing, leaving behind open spaces at their former locations. The systemic release of V1-2 significantly reduced the development of the neointimal plaque area from 1.0Ϯ0.4 to 0.5Ϯ0.8 mm 2 (Pϭ0.047) ( Figure 5B ). Representative OCT frames are shown in Figure 5C . OCT-derived luminal obliteration ( Figure 5D ) was 12.2Ϯ9.8% in saline-treated rats and was significantly reduced by a 6-week treatment with V1-2 to 8.0Ϯ2.0% (Pϭ0.028).
Intimal Hyperplasia in Stented Aortas
Discussion
Clinical results of percutaneous coronary interventions with or without stenting have been limited by restenosis and patients frequently require repeat revascularization procedures. VSMC proliferation and migration with subsequent synthesis of extracellular matrix are central cellular events resulting in neointimal formation. Rat models of aortic balloon injury with 14 and without 15 subsequent stent placement are established models for the development of arterial restenosis and have been used in this study.
Role of PKC in the Development of Intimal Hyperplasia
Although the importance of PKC signaling for VSMC growth and restenosis has been shown previously, 16 the specific roles of its isoforms remained unknown. We used a selective PKC activator and inhibitor, respectively, to elucidate the role of PKC in vascular restenosis. In a rat model of balloon injury, we here show that sustained PKC activation significantly increases neointimal hyperplasia, whereas it is reduced with sustained PKC inhibition. The suppression of neointimal development by PKC inhibition could be shown to result from an antiproliferative capacity of V1-2 in vivo. The cellularity of the neointima and the neointimal fractional area of fibrosis were found to be similar among groups. Therefore, both cellular proliferation and the increase of extracellular fibrosis seem to be affected to similar extents by PKC modulation. Reendothelialization is crucial for physiological healing of mechanically injured arteries. V1-2 treatment, although shown to inhibit in vitro EC proliferation, did not prevent reendothelialization until 4 weeks after injury. Our data, however, cannot determine whether endothelial healing was slowed down by PKC inhibition, because only 1 time point was assessed.
Molecular Basis of PKC Inhibition on PDGF-Stimulated VSMC Proliferation
PDGF induces VSMC proliferation by triggering the activation of both the ERK/mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt pathways. 17 To further examine the molecular basis for the inhibition of VSMC proliferation in rat aortas treated with V1-2, we used VSMC in primary cultures. V1-2 treatment decreased PDGF-induced PKC activation and cell proliferation in VSMC cultures in vitro. ERK is a key transducer of extracellular signals and promotes cell growth and migration. ERK1 and ERK2 play pivotal roles in proliferation of VSMC in vitro and in vivo. PDGF-induced proliferation is inhibited by dominant negative mutants 18 or antisense oligonucleotides 19 of ERKs. In addition, dominant negative mutation of Akt causes delays in G 1/2 exit in the cell cycle and controls proliferation of primary rat aortic VSMC. 20 Independent but synergistic effects of the phosphatidylinositol 3-kinase-Akt pathway and the MEK1/2-ERK pathway in PDGF-induced responses were observed using inhibitors of these kinases, LY294002 and PD98059, respectively. 13 In addition to the relationship between ERK activity and VSMC proliferation, a correlation between ERK and neointimal hyperplasia in rat aorta has been previously observed following balloon angioplastyinduced injury. 18, 21 Mechanical injury-induced VSMC proliferation involves ERK phosphorylation, 22 and ERK activation is among the earliest of biochemical changes detected after arterial injury. 23 ERK transmits mitogenic signals by translocation to the nucleus where multiple genes implicated in the pathogenesis of atherosclerosis and restenosis are induced. 24 Here, we showed that the PKC inhibitor V1-2 did not affect early PDGF-induced ERK and Akt activation, suggesting that PKC is probably not an immediate upstream regulator of these enzymes. However, after 6 hours of PDGF stimulation, ERK levels were significantly decreased following V1-2 treatment, which resulted in decreased amounts of active ERKs in PDGF-stimulated VSMC. PKC activation may also control ERK activity by reducing protein stability and/or decreasing its expression in VSMC. Saito et al 25 reported involvement of PKC in the activation of Grb2associated binder-1, an adapter protein related to the insulin receptor substrate family. Because ERK2 is downstream of Grb2-associated binder-1, the PKC-mediated PDGF effect that we observed may be due to inhibition of the PKCmediated PDGF-Grb2-associated binder-1 pathway activation. Although we only found mild decreases of Akt levels by PKC inhibition in vivo, Akt phosphorylation levels were significantly decreased in vitro by V1-2 treatment when determined 6 hours after PDGF treatment. These data suggest that PKC also controls Akt activity by direct or indirect phosphorylation in VSMC. However, the moderate Ϸ12% (versus saline) to 29% (versus TAT 47-57 ) reduction of Akt activity observed in our V1-2-treated balloon-denuded aortas failed to reach significance.
PKC inhibition may also attenuate VSMC chemotaxis following stimulation with PDGF. ERK activation is required for PDGF-induced VSMC chemotaxis 26 as well as for hyperglycemia-induced chemotaxis of VSMC and cross-talk between ERK and Akt signals. 27 Therefore, although not assessed directly in this study, inhibition of chemotaxis of VSMC may also contribute to the benefit of V1-2 treatment on neointimal hyperplasia.
PKC is the only PKC isozyme that has been considered an oncogene, because it collaborates with Ras/Raf/ERK and Akt pathways to regulate cell survival and death. 28 Reverse, cytosolic translocation of PKC was shown to correlate with ceramideinduced apoptosis in leukemic cells. 29 PKC knockout mice exhibited significantly decreased survival, 30 whereas overexpression of PKC in rat embryo fibroblasts inhibited apoptosis induced by cisplatin. 31 Antiapoptotic PKC further enhances antiapoptotic Bcl-2 members while inhibiting the proapoptotic members of the family. 32 Our results reveal mild antiapoptotic effects of PKC activation in VSMC and demonstrate that PKC inhibition by V1-2 significantly increases apoptosis. In the context of postangioplasty restenosis, the inhibition of VSMC proliferation and the induction of VSMC apoptosis is appealing and has led to regression of experimental vascular lesions. 33 However, VSMC apoptosis in advanced plaques may also contribute to fibrous cap weakening and thereby promote plaque rupture and vessel thrombosis.
PKC Inhibition for the Prevention of Restenosis After Stent Placement
Driven by the success of reducing arterial restenosis with PKC inhibition, we next determined whether the effect would reproduce in a model of restenosis following stent placement. Because the PKC inhibitor V1-2 is a peptide, we could not use it for stent coating, and the drug delivery again was performed systemically via SC pumps. V1-2 significantly reduced both neointimal plaque area as determined by histology and luminal obliteration quantified by OCT. Similarly, the first studies demonstrating inhibition of restenosis by sirolimus were done using systemic drug administration. 34 In conclusion, PKC seems to be centrally involved in the development of neointimal hyperplasia, because contrarious modulations of PKC activation result in opposing effects. Interference with PKC-mediated activation of downstream PDGF pathway enzymes by V1-2 may be the mechanism of action. Targeting PKC may be a novel approach to control arterial restenosis. 
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